By Fineline Cube Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the Phase III international multicenter clinical study (AURA-2, NCT04740671) of HLX04-O for the treatment of wet age-related macular degeneration (wAMD) has met its prespecified primary endpoints. The ophthalmic formulation, optimized from Hanbeitai (bevacizumab biosimilar), demonstrated non-inferiority to ranibizumab with a favorable safety profile in head-to-head comparison.
Clinical Trial Milestone
| Item | Detail |
|---|---|
| Company | Shanghai Henlius Biotech Inc. (HKG: 2696) |
| Study Name | AURA-2 (NCT04740671) |
| Trial Phase | Phase III, international multicenter |
| Primary Indication | Wet age-related macular degeneration (wAMD) |
| Comparator | Intravitreal (IVT) injection of ranibizumab |
| Primary Endpoint | Mean change from baseline in best-corrected visual acuity (BCVA) at Week 36 and Week 48 |
| Key Result | Non-inferiority demonstrated vs. ranibizumab with favorable safety profile |
Product Profile & Development Strategy
- Product Name: HLX04-O – ophthalmic formulation optimized for ocular delivery
- Base Molecule: Derived from Hanbeitai (bevacizumab biosimilar)
- Mechanism of Action: Recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody
- Optimization Rationale: Specifically engineered to address ophthalmic application requirements and delivery challenges
- Clinical Differentiation: Potential cost advantage over existing anti-VEGF therapies while maintaining comparable efficacy
Strategic Partnership Framework
Henlius has established a comprehensive development and commercialization partnership for ophthalmic applications:
- Partner: Essex Bio-Investment Limited
- Rights Granted: Exclusive worldwide rights to ophthalmic use and/or therapies of Hanbeitai
- Development Model: Joint product development collaboration
- Cost Sharing Structure: Henlius (20%) / Essex (80%) of development costs and expenses
- Geographic Scope: Global exclusivity for ophthalmic indications
Market Impact & Competitive Landscape
- wAMD Market Size: Affects approximately 20 million people globally with significant unmet need for cost-effective treatments
- Anti-VEGF Dominance: Current standard of care dominated by high-priced biologics including ranibizumab, aflibercept, and brolucizumab
- Biosimilar Opportunity: HLX04-O represents potential first bevacizumab-derived ophthalmic biosimilar with proven non-inferiority to established therapy
- Pricing Advantage: Biosimilar pricing model could significantly reduce treatment costs and improve patient access
- Regulatory Pathway: Positive Phase III data supports regulatory submissions in multiple jurisdictions
- Commercial Strategy: Partnership with Essex leverages specialized ophthalmic expertise and global commercial infrastructure
Strategic Outlook
The successful AURA-2 trial positions HLX04-O as a potential game-changer in the wAMD treatment landscape, offering comparable efficacy to established anti-VEGF therapies at potentially lower cost points. The strategic partnership with Essex Bio-Investment provides Henlius with specialized ophthalmic development expertise and global commercial reach, while maintaining significant economic participation through the favorable cost-sharing structure. This achievement reinforces Henlius’ position as a leader in biosimilar innovation and expands its therapeutic footprint beyond oncology into high-value ophthalmic indications.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, market adoption, and commercial performance. Actual results may differ due to regulatory review outcomes, competitive dynamics, pricing pressures, and market acceptance.-Fineline Info & Tech